Health
Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines
- Drugmaker beat expectations on strong sales of Covid shots
- Company keeps full-year outlook, maintains cost-cutting plan
This article is for subscribers only.
Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., who has been a vocal opponent of the company’s top-selling shot, got one step closer to becoming US health secretary.
The news about Kennedy’s nomination moving forward came during Pfizer’s fourth-quarter earnings call Tuesday, where executives were explaining how the company’s Covid pill and vaccine outperformed Wall Street’s forecast and should continue to bring in around $10 billion a year. Kennedy, who has described Pfizer’s top-selling shot as the “deadliest vaccine ever made,” had cleared a key Senate committee on the way to confirmation as the next head of the US Department of Health and Human Services.